8-K/A: Tevogen Bio Holdings Files Amended 8-K, Corrects Audit Reference and Includes Financials

Tevogen Bio Holdings Inc. files an amendment to its Form 8-K to correct a reference to private company auditing standards and includes audited financial statements for 2022 and 2023.

Summary

• Tevogen Bio Holdings Inc. filed an amendment to its Form 8-K to remove a reference to private company auditing standards from the report of KPMG LLP.
• The amendment includes the audited financial statements of Tevogen Bio Inc. for the years ended December 31, 2023 and 2022.
• The financial statements show a net loss of $60.48 million in 2023, compared to a net loss of $22.04 million in 2022.
• The company's total assets decreased from $7.74 million in 2022 to $5.51 million in 2023.
• The company's total liabilities increased significantly from $41.69 million in 2022 to $99.93 million in 2023, primarily due to convertible promissory notes.
• The company has incurred losses and negative cash flows since inception, raising substantial doubt about its ability to continue as a going concern.
• Management is exploring various strategies to secure additional funding, including private placements, licensing agreements, and public offerings.

Sentiment

Score: 3

Explanation: The document reveals significant financial challenges, including a substantial increase in net loss, a decrease in cash, a large increase in liabilities, and a going concern warning. While the company is pursuing funding, the overall sentiment is negative due to the financial instability.

Positives

• The company has completed a Phase 1 proof-of-concept trial for its first clinical product, TVGN 489.
• The company is actively pursuing additional funding through various strategies.

Negatives

• The company has incurred significant losses and negative cash flows since its inception.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company's cash balance has significantly decreased.
• The company's liabilities have increased substantially due to convertible promissory notes.
• The company's net loss has increased significantly year over year.

Risks

• The company may not be able to obtain financing on acceptable terms or at all.
• The company may be required to delay, reduce, or eliminate research and development programs if funding is not secured.
• The company's research and development projects may not be successful.
• The company's products may not obtain necessary regulatory approval.
• The company's approved products may not be commercially viable.

Future Outlook

Management is evaluating strategies to obtain additional funding, including private placements, licensing arrangements, and public offerings. The company anticipates incurring additional losses until it can generate significant sales from its product candidates.

Management Comments

• Management believes that cash of $1,052,397 as of December 31, 2023 as well as $2,000,000 to Tevogen Holdings from a Series A Preferred Stock financing in February 2024 and $1,200,000 in connection with the Series A-1 Preferred Stock financing thereafter is not sufficient to sustain planned operations for 12 months from the issuance date of these financial statements.
• Management is currently evaluating different strategies to obtain the additional funding for future operations for subsequent years.

Industry Context

The company operates in the biotechnology industry, which is characterized by high research and development costs and the need for regulatory approvals. The company's focus on precision T cell therapies places it in a competitive and rapidly evolving sector.

Comparison to Industry Standards

• The company's significant net losses and cash burn are not uncommon for clinical-stage biotechnology companies, particularly those focused on novel therapies.
• Companies like Adaptimmune Therapeutics and Allogene Therapeutics, which are also developing cell therapies, have faced similar challenges in terms of funding and achieving profitability.
• The high level of debt through convertible promissory notes is a risk factor that is not always seen in companies of this stage, and is a potential concern for investors.
• The company's going concern warning is a significant concern, and is not always seen in companies of this stage, and is a potential concern for investors.

Related Party Transactions

• In January 2023, the Company issued 40,000 Performance-Based RSUs to the wife of the Companys chairman and chief executive officer for advisory services provided to the Company.
• In January 2023, the Company issued 20,000 Performance-Based RSUs to Mehtaphoric Consulting Inc., a company controlled by the daughter of the Companys chief financial officer, for information technology services provided to the Company.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern warning.
• Employees may be impacted by potential delays or reductions in research and development programs.
• Customers may be affected by potential delays in product development and commercialization.
• Suppliers and creditors face increased risk due to the company's financial challenges.

Next Steps

• The company needs to secure additional funding to continue operations.
• The company will continue to develop its product candidates.
• The company will seek regulatory approvals for its products.
• The company will explore strategic alliances and other arrangements.

Key Dates

Keywords

Tevogen Bio, Financial Statements, Form 8-K, Audited Financials, Going Concern, Convertible Promissory Notes, Biotechnology, Immunotherapy, Clinical Stage, Net Loss